Sculptra Before and After: 1, 2 and 3 Vials

One Sculptra vial is 367.5 mg of poly-L-lactic acid powder, with sodium carboxymethylcellulose and mannitol, in a vial meant for one patient and one session, and it has to be mixed with sterile water before any injection.

What you see in the mirror right after a session is not the result.

The label says that immediate fullness is mostly water swelling, which resolves within hours to a few days, after which the original contour deficiency reappears; correction then develops gradually, the area is meant to be under-corrected at each session, and at least 3–4 weeks should pass before the area is reassessed.

In the first days, the label says the common redness, swelling or bruising typically resolve within hours to one week, and makeup may be applied a few hours after treatment if there are no complications.

So a genuine Sculptra before-and-after is measured in weeks and months, not in what the mirror shows on treatment day.

The label's caps set the scale of a session: up to 4.5 mL per nasolabial fold and up to 9 mL per cheek with the 8 mL reconstitution — and in the cheek-wrinkle study, subjects received at most two vials per session, one per side.

So in that study a session held two vials at most — one per side — and a third vial only entered the count across sessions: subjects were treated at four-week intervals for up to four sessions, with 95, 86 and 67 subjects receiving a 2nd, 3rd and 4th session.

The median injected volume per session was 16.0 mL across both sides, and the mean total came to 54.11 mL per subject — which works out to about six vials mixed to 9 mL each, our arithmetic from the study figures rather than a labeled amount.

As for what that produced, 70.7% of treated subjects were rated improved at month 12, against 25.9% of untreated controls, and 76.9% (50 of 65) were still responders at month 24 in the extension study.

Galderma, Sculptra's maker, says results can be seen as early as 1 month after treatment and puts the duration at up to 2 years — a manufacturer statement, not a labeled one.

What vials cost, the full side-effect list and the aftercare rules are on the Sculptra guide; this page stays on what the change looks like.

"Full face" is not one of Sculptra's approvals, because the approvals are written for named areas: shallow to deep nasolabial fold contour deficiencies and other facial wrinkles, and fine lines and wrinkles in the cheek region.

The label gives per-session caps for the areas it covers — 4.5 mL per nasolabial fold, 9 mL per cheek — but no whole-face vial count, and we found no label, professional body or peer-reviewed source that sets a standard vial count for any face area.

A before-and-after labeled "full face" is therefore best read as a series of sessions: in the study, sessions came at four-week intervals, the median session volume was 16.0 mL across both sides, and the mean total was 54.11 mL per subject.

The label also says safety and effectiveness have not been evaluated when Sculptra is injected in larger amounts, at different frequencies, or at sites other than its approved uses — so there is no tested full-face amount to quote, whatever a gallery photo suggests.

Cheeks are the area with published numbers behind it: Sculptra is approved for fine lines and wrinkles in the cheek region, the cheek study capped each side at one vial per session, and 70.7% of treated subjects were rated improved at month 12.

Under the eyes is different: the label says use in the lips and periorbital area has not been evaluated, with published literature reporting more nodules around the eyes, and that Sculptra must not be injected into the red part (vermilion) of the lips.

As of October 2026, four US fillers carry an FDA-approved under-eye (infraorbital hollow) indication — Juvéderm Volbella XC (2021), Restylane Eyelight (2023), Belotero Balance (+) Lidocaine (2023) and RHA Redensity Eye / Eye Lido (2026) — and using any other filler under the eyes, Sculptra included, is off-label.

That is why under-eye filler is its own topic.

Temples and jawline have no Sculptra approval: the label says safety and effectiveness have not been evaluated at sites other than its approved uses, so a temple or jawline before-and-after you see online is off-label use.

Sculptra's approval language does not separate men from women: the 2009 aesthetic indication covers shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in immune-competent people, and the cheek indication covers fine lines and wrinkles in the cheek region.

Sculptra's first US approval came in 2004, for HIV-associated facial fat loss.

We could not find a study that reports Sculptra's results separately for men, so the percentages on this page are not split by sex.

The practical parts come from the same label for everyone: one 367.5 mg vial size, the session caps per approved area, the gradual timeline and the off-label limits described above.

A licensed provider can tell you how the study populations compare with your face.